97 related articles for article (PubMed ID: 33764155)
1. Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥65 years.
Sieluk J; Yang L; Haiderali A; Huang M; Hirshfield KM
Future Oncol; 2021 Jul; 17(20):2581-2592. PubMed ID: 33764155
[No Abstract] [Full Text] [Related]
2. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
Aly A; Shah R; Hill K; Botteman MF
Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
4. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.
Hsu JY; Chang CJ; Cheng JS
Sci Rep; 2022 Jan; 12(1):729. PubMed ID: 35031634
[TBL] [Abstract][Full Text] [Related]
5. Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016.
Sieluk J; Haiderali A; Huang M; Yang L; Hirshfield KM
Future Oncol; 2021 Mar; 17(9):1039-1054. PubMed ID: 33261515
[No Abstract] [Full Text] [Related]
6. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
7. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
9. Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.
Skinner KE; Haiderali A; Huang M; Schwartzberg LS
Future Oncol; 2021 Mar; 17(8):931-941. PubMed ID: 33207944
[No Abstract] [Full Text] [Related]
10. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
11. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
12. End-of-life care for lung cancer patients in the United States and Ontario.
Warren JL; Barbera L; Bremner KE; Yabroff KR; Hoch JS; Barrett MJ; Luo J; Krahn MD
J Natl Cancer Inst; 2011 Jun; 103(11):853-62. PubMed ID: 21593012
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
Kimura T; Takami T; Piao Y; Ntalla I; Saji S
Breast Cancer Res Treat; 2024 Jul; 206(1):91-103. PubMed ID: 38704772
[TBL] [Abstract][Full Text] [Related]
15. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]